Get started
IMUGENE LIMITEDIMUGENE LIMITEDIMUGENE LIMITED

IMUGENE LIMITED

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

IMU trade ideas

Imugene Limited (ASX: IMU) Director's Increase Stake"Imugene Limited (ASX: IMU) Director's Stake Update: On 12th Jan '24, a director affirmed their commitment by acquiring 1M RSUs at no cost, signaling bullish sentiment. Pre-acquisition, the director held 600K options and 20.73M shares, maintaining these post-acquisition. No options or shares were sold, implying a strong belief in the future of IMU. This strategic holding pattern may suggest an insider's positive outlook, potentially interesting for investors monitoring IMU's stock." investorhub.imugene.com
ASX:IMULong
by PPonBIN
Finer Market Points: ASX Top 10 Momentum Stocks: 30 Nov 2023ASX:SHN ASX:TCG ASX:TG6 NYSE:STK SET:PLT ASX:VMM ASX:EQN ASX:FL1 ASX:IMU ASX:4DX Momentum-leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Sunshine Metals Limited (SHN): A mining company with various projects, including gold, copper, and base metals, across Australia. Turaco Gold Limited (TCG): Gold miner with projects near Ghana's border. TG Metals Limited (TG6): WA miner focused on Ni, Li, Gold in Lake Johnston Greenstone Belt. Strickland Metals Limited (STK): A mineral exploration company focused on gold, copper, Zi, Pb, and Silver in Western Australia. Plenti Group Limited (PLT): A financial technology company specializing in consumer and auto loans, renewable energy financing, and other lending services in Australia. Viridis Mining and Minerals Limited (VMM): Exploring gold, Ni, Cu, PGE, and Kaloin-halloysite assets in Canada and WA SA and NSW. Equinox Resources Limited (EQN): Focused on the exploration and development of mineral resources, including gold and base metals. First Lithium Limited (FL1): Lithium and Alkali explorer primarily active in Northern Chile. Imugene Limited (IMU): Clinical-stage immuno-oncology biotech attempting to activate the immune system of cancer patients to identify and eradicate tumors. 4Dmedical Limited (4DX): Software company focusing on a four-dimensional lung imaging platform, which develops pipeline products attempting to assist physicians to more effectively diagnose and manage patients with lung disease.
ASX:IMU
by ch886
Box and Squeeze Strategy - Darvas InspiredDescription The "Combined Box and Squeeze Strategy" is a comprehensive trading script developed for the TradingView platform. It merges two distinct analytical approaches: "The Box Percent Strat" and "Squeeze Box ," offering traders a multifaceted tool for market analysis. Key Features Box Percent Strat: This component of the strategy dynamically adjusts trading boxes based on price movements. The top and bottom of the box are recalculated as the market evolves, providing visual cues for significant price levels. Squeeze Box : Focused on volatility and market squeeze, this part of the strategy utilizes Bollinger Bands and a custom Moving Average calculation. It identifies periods of low volatility (squeeze) and plots high and low squeeze box levels, aiding in the identification of breakout opportunities. Dynamic Moving Average Calculation: The script includes various options for moving average calculations, such as EMA, SMA, WMA, VWMA, and more. Users can select their preferred type, which is then integrated into both the box calculations and squeeze analysis. Trading Signals: Entry and exit points are suggested based on the strategy's logic, which combines box breakouts and moving average trends. These signals can be used to inform trading decisions in conjunction with a user's existing strategy. Visual Plotting: Key levels, including box boundaries and moving averages, are plotted directly on the chart, making the analysis straightforward and visually accessible. Usage Ideal for various markets and timeframes. Can be customized to fit individual trading styles by adjusting input parameters. Should be used in conjunction with proper risk management strategies. Disclaimer This script is provided for educational purposes and should be tested thoroughly in a simulated environment before being applied to live trading. Users should trade based on their discretion and understanding of the financial markets.
ASX:IMULong
by PPonBIN
Trend Following and SMA CrossDescription: This innovative trading strategy is a synergistic blend of two proven approaches: Trend Following and Simple Moving Average (SMA) Crossover. It harnesses the strengths of each to offer a more robust trading system designed for a variety of markets. Key Features: Trend Following Component: Utilizes an Exponential Moving Average (EMA) and a Volume-Weighted Moving Average (VWMA) to establish the direction of the trend. The strategy enters a long position when the price crosses above the VWMA and enters a short position when it crosses below, provided the price is already trending as indicated by the EMA. SMA Crossover Component: Employs a fast SMA and a slow SMA to pinpoint momentum shifts. A buy signal is generated when the fast SMA crosses above the slow SMA, indicating a potential upward price movement. Conversely, a sell signal is triggered when the fast SMA crosses below, suggesting a downward trend. Customizable Parameters: Traders can input their own values for the lengths of the EMA, VWMA, and both SMAs, allowing for personalized strategy tuning. Server-Side Integration: Equipped with the capability to send trade execution alerts to an Automated Trading Platform (ATP) via webhooks, enabling automated trading. TradingView Alerts: Each trade signal can be set up to notify you through TradingView's alert system, keeping you informed of potential trades. Strategy Logic: Entry Logic: Trend Following: A position is entered following a price crossover with the VWMA, considering the trend direction indicated by the EMA. SMA Crossover: Trades are triggered on the crossovers of the fast and slow SMAs, filtering entries based on the broader trend and position initiation conditions. Exit Logic: Trend Following: Positions are exited when the opposite VWMA crossover occurs. SMA Crossover: The strategy exits positions when a contrary SMA crossover is observed. Visualization: The strategy plots the EMA and VWMA trend lines along with the fast and slow SMAs directly on the TradingView chart, providing clear visual cues for entry and exit points. Usage: This strategy is versatile and can be applied to various asset classes, including forex, equities, and cryptocurrencies. Ideal for traders who appreciate a systematic approach that combines different methodologies for entry and exit signals. A backtesting feature allows traders to assess the strategy's performance historically before applying it to live markets. Disclaimer: This strategy is presented for educational purposes and should not be construed as financial advice. Thorough backtesting and demo trading are recommended to evaluate the strategy's effectiveness in current market conditions. Users should employ proper risk management and consider slippage and trading fees when deploying this strategy.
ASX:IMU
by PPonBIN
IMU @ 18 NOV 2021Text me if you have any questions/comments for me. ----- IMU - Previous analysis was done on 4 Oct (red arrow) – suggested waiting for a successful rebound around 47.5 cents before plotting entry - Since then, the stock has created a new high, retraced, and looks to be rebounding off the short-term support - If have taken the entry suggestion, you should be having roughly 19% gains in roughly 3 weeks - A successful rebound look to be around 60 cents - R is more than 10% - Strategy-to-buy (DYOR) – Suggest waiting for a successful rebound before plotting entry
ASX:IMU
by Jerm88
IMUGENE Run Complete?Imugene (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. 3 Scenarios identified Bullish: - MACD still Bullish - Volume increasing - RSI still trending Bullish although currently Overbought - Bullish bounce off .382 Fib Retracement Bullish price action continues and breaks Daily Resistance. Higher targets can be identifed by use of Trend Based Fib Extension. Consolidation: - Double Top off Daily Resistance - MACD Weakening - RSI Overbought After a great run price could consolidate underneath Daily Resistance for a short time, which could build a potential Bullish/Bearish Pattern. Im looking at the .382 Fib Retracement as the next level of Major Resistance. Bearish: - MACD Weakening - RSI Overbought - Fractal Pattern Completed - Double Top off Daily Resistance If the Fib Retracement level 0.382 fails as support look for the Golden Pocket 0.5-0.618 "DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
ASX:IMU
by Trader_Johnni
$IMU:ASX - IMUGENE LIMITED - Big buy side before conferenceWill be interesting to see if IMU gets more of a bump during and after its conference today. MASSIVE buy side demand with 220 buyers for 107,568,372 units vs 61 sellers for 26,085,482 units. Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
ASX:IMULong
by zAngus